Orchestra BioMed Holdings, Inc. (OBIO)

Market Cap	113.79M
Revenue (ttm)	2.64M
Net Income (ttm)	-61.02M
Shares Out	38.31M
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	796,776
Open	2.620
Previous Close	2.530
Day's Range	2.580 - 3.030
52-Week Range	2.430 - 8.870
Beta	0.62
Analysts	Strong Buy
Price Target	15.00 (+405.05%)
Earnings Date	May 12, 2025

About OBIO

Orchestra BioMed Holdings, Inc. operates as a biomedical company. The company’s flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chron...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 70
• Stock Exchange: NASDAQ
• Ticker Symbol: OBIO
• Website: https://orchestrabiomed.com

Financial Performance

In 2024, Orchestra BioMed Holdings's revenue was $2.64 million, a decrease of -4.42% compared to the previous year's $2.76 million. Losses were -$61.02 million, 24.2% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for OBIO stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 405.05% from the latest price.

Price Target

$15.0

(405.05% upside)

Analyst Consensus: Strong Buy